Phase 2 B-cell Lymphoma Clinical Trials
90 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 90 trials
Recruiting
Phase 2
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell Lymphoma+12 more
National Cancer Institute (NCI)120 enrolled82 locationsNCT06649812
Recruiting
Phase 2
Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma
Large B-cell Lymphoma
M.D. Anderson Cancer Center10 enrolled1 locationNCT07316010
Recruiting
Phase 1Phase 2
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
Burkitt LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsDouble-Expressor Lymphoma
National Cancer Institute (NCI)50 enrolled4 locationsNCT07069699
Recruiting
Phase 1Phase 2
Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma
CNS MetastasesB-cell Lymphoma RecurrentB-cell Lymphoma Refractory
Samsung Medical Center37 enrolled2 locationsNCT06552559
Recruiting
Phase 1Phase 2
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
Relapsed and/or Refractory B-cell Lymphoma
Kite, A Gilead Company247 enrolled18 locationsNCT04989803
Recruiting
Phase 2
Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell LymphomaRefractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified+5 more
City of Hope Medical Center43 enrolled3 locationsNCT07365306
Recruiting
Phase 1Phase 2
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Refractory CancerB-cell LymphomaB-cell Malignancy+1 more
BeOne Medicines80 enrolled50 locationsNCT06634589
Recruiting
Phase 1Phase 2
Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology
B-cell Lymphoma RecurrentRefractory B-Cell Lymphoma
Instituto de Investigación Biomédica de Salamanca27 enrolled8 locationsNCT06378190
Recruiting
Phase 2
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Chronic Myelomonocytic LeukemiaRecurrent LymphomaRecurrent Diffuse Large B-Cell Lymphoma+5 more
Mayo Clinic80 enrolled4 locationsNCT03418038
Recruiting
Phase 1Phase 2
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
Diffuse Large B Cell LymphomaHodgkin LymphomaMantle Cell Lymphoma+6 more
New York Medical College20 enrolled1 locationNCT04491370
Recruiting
Phase 2
Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial
Nodular Lymphocyte Predominant B-Cell LymphomaRecurrent Nodular Lymphocyte Predominant B-Cell LymphomaRefractory Nodular Lymphocyte Predominant B-Cell Lymphoma
National Cancer Institute (NCI)70 enrolled35 locationsNCT05886036
Recruiting
Phase 1Phase 2
Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas
B-cell Lymphoma Refractory
National University Hospital, Singapore30 enrolled1 locationNCT07319676
Recruiting
Phase 2
CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma
Large B-Cell Lymphoma (LBCL)
Zhejiang University40 enrolled1 locationNCT04661020
Recruiting
Phase 2
Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
Large B-cell Lymphoma
H. Lee Moffitt Cancer Center and Research Institute27 enrolled1 locationNCT06104592
Recruiting
Phase 2
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
Large B-cell Lymphoma
H. Lee Moffitt Cancer Center and Research Institute28 enrolled1 locationNCT06760156
Recruiting
Phase 1Phase 2
Efficacy and Safety of CD19/CD20 CAR/TRuC-T in Relapsed/Refractory B-Cell Lymphoma
Relapsed/Refractory B-cell Lymphoma
Shenzhen University General Hospital20 enrolled1 locationNCT07508605
Recruiting
Phase 2Phase 3
NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)
Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Relapsed/Refractory Non-Hodgkin Lymphoma+2 more
Health Institutes of Turkey40 enrolled4 locationsNCT07502118
Recruiting
Phase 1Phase 2
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaChronic Lymphocytic Leukemia+8 more
Vironexis Biotherapeutics Inc.32 enrolled9 locationsNCT06533579
Recruiting
Phase 2
Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation
Diffuse Large B-Cell Lymphoma (DLBCL)
The First Affiliated Hospital of Soochow University35 enrolled1 locationNCT07499271
Recruiting
Phase 2
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
Diffuse Large B-Cell Lymphoma (DLBCL)
Ou Bai, MD/PHD50 enrolled1 locationNCT07493148